Cognito Therapeutics presented new data on its investigational Spectris therapy for Alzheimer’s disease at the ADPD 2026 conference, according to the company. The results add to a growing body of clinical and biomarker evidence supporting the non-invasive neurostimulation platform, which is designed to modulate brain activity through synchronized light and sound stimulation.
According to the company, the data include analyses of clinical outcomes alongside biomarker findings that support the therapy’s potential neuroprotective effects. Spectris is designed to stimulate gamma frequency brain waves, which are associated with memory and cognitive function and are disrupted in Alzheimer’s disease. The company claims this mechanism may help preserve neuronal connections and slow disease progression.
The company reported that prior studies of Spectris have demonstrated preservation of brain structure, cognition and daily function in patients with mild to moderate Alzheimer’s disease. In earlier trials, treatment was associated with reduced decline in cognitive and functional measures as well as slower brain atrophy compared with control groups. These findings are supported by biomarker analyses indicating changes in proteins linked to synaptic function, immune regulation and neuroprotection.
Spectris is delivered through a non-invasive, at-home device that provides daily sessions of visual and auditory stimulation. According to the company, this approach is intended to offer a scalable alternative to pharmacological treatments, with a favorable safety profile and no reported amyloid related imaging abnormalities in clinical studies.
Cognito Therapeutics is advancing Spectris in the ongoing HOPE Phase 3 trial, which has enrolled approximately 670 participants across multiple sites in the United States. The company expects the study to further evaluate the therapy’s ability to slow cognitive and functional decline and support potential regulatory pathways for broader use.
